Stevanato Group S.P.A. is a global leader in the design and manufacturing of drug containment and delivery solutions for the pharmaceutical and biotechnology industries
The company specializes in producing high-quality glass vials, syringes, and other packaging solutions that ensure the safe and effective delivery of medicines. Additionally, Stevanato Group offers integrated technologies and services, focusing on enhancing the performance of its products through innovative packaging systems and automation processes. The company’s commitment to quality, safety, and sustainability makes it a trusted partner for healthcare organizations seeking reliable and efficient solutions for their drug delivery needs.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2024 on Thursday, March 6, 2025, at 6:30 a.m.(ET).
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the CJS Securities 25th Annual “New Ideas for the New Year” Investor Conference on Tuesday, January 14, 2025, at 8:00 a.m. ET.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET).
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, announced today the expansion of its Vertiva® platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva® easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-content bolus injections. This flexibility makes the platform ideal for administering a wide range of small molecule and biologic therapies, enabling treatment for conditions such as cardiovascular and metabolic disorders, oncology, immunology, and pain management.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together with Gerresheimer AG (MDAX: GXI) and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), announced today that they have entered into a strategic industry alliance ("Alliance for RTU") to support market adoption of Ready-to-Use (RTU) vials and cartridges.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the second quarter of 2024 on Tuesday, August 6, 2024, at 6:30 a.m. (ET).
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life science industries, today announced the inauguration of its Cisterna di Latina plant.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Mr. Moro will remain on the Company’s Board of Directors.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders (“AGM”) held virtually on May 22, 2024, have passed.
Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences.
